Dr Aggarwal on the Activity of BXCL701 Plus Pembrolizumab in SCNC mCRPC
Rahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype.